Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Farmers Insurance
US Army
Federal Trade Commission
Fish and Richardson

Generated: July 26, 2017

DrugPatentWatch Database Preview

Dextroamphetamine sulfate - Generic Drug Details

« Back to Dashboard

What are the generic sources for dextroamphetamine sulfate and what is the scope of dextroamphetamine sulfate patent protection?

Dextroamphetamine sulfate
is the generic ingredient in five branded drugs marketed by Actavis Elizabeth, Ferndale Labs, Glaxosmithkline, Lannett, Nesher Pharms, Able, Mast Mm, Purepac Pharm, Halsey, Novel Labs Inc, Mikart, Mylan Pharms Inc, Teva, Mallinckrodt, Mayne Pharma, Tris Pharma Inc, Avanthi Inc, Shire, Epic Pharma Llc, Barr, Idt Australia Ltd, Sandoz, Outlook Pharms, Amedra Pharms, Vitarine, Aurolife Pharma Llc, and Vintage Pharms Llc, and is included in thirty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for dextroamphetamine sulfate. Twenty-five suppliers are listed for this compound.

Summary for Generic Name: dextroamphetamine sulfate

Drug Master File Entries: see list17
Suppliers / Packagers: see list25
Clinical Trials: see list653
Therapeutic Class:Central Nervous System Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:dextroamphetamine sulfate at DailyMed

Pharmacology for Ingredient: dextroamphetamine sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nesher Pharms
dextroamphetamine sulfate
TABLET;ORAL206588-002Mar 28, 2016AARXNoNo► Subscribe► Subscribe► Subscribe
dextroamphetamine sulfate
TABLET;ORAL040361-002Jan 31, 2001AARXNoYes► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
dextroamphetamine sulfate
CAPSULE, EXTENDED RELEASE;ORAL206735-001Jan 27, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Amedra Pharms
dextroamphetamine sulfate
CAPSULE, EXTENDED RELEASE;ORAL017078-001Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
dextroamphetamine sulfate
TABLET;ORAL083735-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Argus Health
Federal Trade Commission
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus